New Key Statistics Module, Z-Score and F-Score
NAS:VRCA Key Ratios
| Market Cap $ M | 367.78 |
| Enterprise Value $ M | 385.65 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 254.17 |
| Price/Sales | 47.66 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 8.00 |
| EPS (TTM) $ | -1.76 |
| Beneish M-Score | 110.12 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 6.90 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -5.18 |
| EV-to-EBITDA | -5.25 |
| PEG | -- |
| Shares Outstanding M | 42.42 |
| Net Margin (%) | -905.83 |
| Operating Margin % | -838.45 |
| Pre-tax Margin (%) | -905.83 |
| Quick Ratio | 3.04 |
| Current Ratio | 3.17 |
| ROA % (ttm) | -107.39 |
| ROE % (ttm) | -219.61 |
| ROIC % (ttm) | -721.54 |
| Dividend Yield % | -- |
| Altman Z-Score | -4.51 |
VRCA Number of Guru Trades
VRCA Volume of Guru Trades
Gurus Latest Trades with NAS:VRCA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:VRCA is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Verrica Pharmaceuticals Inc Insider Transactions
No Available Data
News about NAS:VRCA
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers